HPA028598

antibody from Atlas Antibodies

Targeting: TFRC CD71, p90, TFR1

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

HPA028598

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA028598, RRID:AB_10601599

Product name

Anti-TFRC

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human TFRC, Gene description: transferrin receptor, Alternative Gene Names: CD71, p90, TFR1, Validated applications: WB, IHC, ICC, Uniprot ID: P02786, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.2 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization

Zhang R, Shen Y, Zhou X, Li J, Zhao H, Zhang Z, Zhao J, Jin H, Guo S, Ding H, Nie G, Zhang Z, Wang Y, Yan X, Fan K
Nature Communications 2025;16(1)

---

Integrating iron metabolism-related gene signature to evaluate prognosis and immune infiltration in nasopharyngeal carcinoma

Su J, Zhong G, Qin W, Zhou L, Ye J, Ye Y, Chen C, Liang P, Zhao W, Xiao X, Wen W, Luo W, Zhou X, Zhang Z, Cai Y, Li C
Discover Oncology 2024;15(1)

---

Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer

Lastwika K, Kunihiro A, Solan J, Zhang Y, Taverne L, Shelley D, Rho J, Randolph T, Li C, Grogan E, Massion P, Fitzpatrick A, MacPherson D, Houghton A, Lampe P
Science Translational Medicine 2023;15(678)

---

MiRNA Deregulation Distinguishes Anaplastic Thyroid Carcinoma (ATC) and Supports Upregulation of Oncogene Expression

Misiak D, Bauer M, Lange J, Haase J, Braun J, Lorenz K, Wickenhauser C, Hüttelmaier S
Cancers 2021;13(23):5913

---

In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy

Fan K, Xi J, Fan L, Wang P, Zhu C, Tang Y, Xu X, Liang M, Jiang B, Yan X, Gao L
Nature Communications 2018;9(1)

---

Mapping molecules in scanning far-field fluorescence nanoscopy

Ta H, Keller J, Haltmeier M, Saka S, Schmied J, Opazo F, Tinnefeld P, Munk A, Hell S
Nature Communications 2015;6(1)

---

PSD-Zip70 Deficiency Causes Prefrontal Hypofunction Associated with Glutamatergic Synapse Maturation Defects by Dysregulation of Rap2 Activity

Mayanagi T, Yasuda H, Sobue K
The Journal of Neuroscience 2015;35(42):14327-14340

---

Hemochromatosis Enhances Tumor Progression via Upregulation of Intracellular Iron in Head and Neck Cancer

Singh S, Lenarduzzi M, Hui A, Yue S, Ito E, Shi W, Williams J, Bruce J, Sakemura-Nakatsugawa N, Xu W, Schimmer A, Liu F
PLoS ONE 2013;8(8):e74075

Immunohistochemistry

Supportive validation

Submitted by

Atlas Antibodies (provider)

Enhanced method

Orthogonal validation

Main image

Experimental details

Immunohistochemistry analysis in human placenta and pancreas tissues using HPA028598 antibody. Corresponding TFRC RNA-seq data are presented for the same tissues.

Sample type

Human

Protocol

Protocol

Orthogonal method

Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

Show more